This segment focuses on the development and commercialization of TYRVAYA (varenicline solution) nasal spray for the treatment of the signs and symptoms of dry eye disease. Research and development activities include post-market studies to evaluate long-term safety and efficacy, as well as exploring new formulations and delivery methods. The technology leverages nicotinic acetylcholine receptor (nAChR) agonists to stimulate tear production. This therapeutic area addresses a significant unmet need in patients suffering from dry eye, improving their quality of life by alleviating discomfort and visual disturbances. Oyster Point Pharma has established a strong market position with TYRVAYA, offering a novel non-artificial tear approach to dry eye management. Future opportunities include expanding the label to include additional patient populations and exploring combination therapies. Regulatory and clinical aspects involve ongoing monitoring of adverse events and compliance with FDA guidelines.

This segment is dedicated to the development of therapies for neurotrophic keratopathy (NK), a rare degenerative corneal disease. Research and development efforts are centered on OC-01 (varenicline solution) nasal spray, currently in Phase II clinical trials for NK. The technology aims to stimulate corneal nerve function and promote healing. This therapeutic area addresses a critical unmet need for patients with NK, who often face vision loss and corneal damage. Oyster Point Pharma is positioned to be a leader in NK treatment if the clinical trials are successful. Future opportunities include advancing the clinical program, securing regulatory approval, and exploring partnerships for commercialization. The regulatory and clinical pathway involves rigorous evaluation of safety and efficacy in NK patients, with the goal of obtaining orphan drug designation and market exclusivity.